{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:07:24Z","timestamp":1790010444306,"version":"4.0.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R34AR084192 (NIAMS) award"],"award-info":[{"award-number":["R34AR084192 (NIAMS) award"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017173","name":"Sj\u00f6gren's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004528"],"award-info":[{"award-number":["UM1TR004528"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004398"],"award-info":[{"award-number":["UM1TR004398"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"DOI":"10.1007\/s40272-026-00772-3","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:47:30Z","timestamp":1790002050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing Sj\u00f6gren\u2019s Disease in Pediatric Patients"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-1823","authenticated-orcid":false,"given":"Sara M.","family":"Stern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3028-4900","authenticated-orcid":false,"given":"Ludovic","family":"Trinquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9760-7196","authenticated-orcid":false,"given":"Marisha E.","family":"Palm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-723X","authenticated-orcid":false,"given":"Nora G.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"772_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clim.2019.04.009","volume":"203","author":"FB Vivino","year":"2019","unstructured":"Vivino FB, Bunya VY, Massaro-Giordano G, Johr CR, Giattino SL, Schorpion A, et al. Sjogren\u2019s syndrome: an update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019;203:81\u2013121.","journal-title":"Clin Immunol"},{"issue":"9482","key":"772_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox RI. Sjogren\u2019s syndrome. Lancet. 2005;366(9482):321\u201331.","journal-title":"Lancet"},{"issue":"7","key":"772_CR3","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1093\/rheumatology\/keaa757","volume":"60","author":"ML Basiaga","year":"2021","unstructured":"Basiaga ML, Stern SM, Mehta JJ, Edens C, Randell RL, Pomorska A, et al. Childhood Sjogren syndrome: features of an international cohort and application of the 2016 ACR\/EULAR classification criteria. Rheumatology (Oxford). 2021;60(7):3144\u201355.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"772_CR4","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1093\/rheumatology\/keae640","volume":"64","author":"SM Stern","year":"2025","unstructured":"Stern SM, Basiaga ML, Cha S, Thatayatikom A, Treemacki EB, Randell RL, et al. Diagnosing a child presenting with symptoms suggesting Sjogren\u2019s disease: a tool for clinical practice. Rheumatology (Oxford). 2025;64(5):3039\u201347.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"772_CR5","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1093\/rheumatology\/keab032","volume":"60","author":"M Ramos-Casals","year":"2021","unstructured":"Ramos-Casals M, Acar-Denizli N, Vissink A, Brito-Zeron P, Li X, Carubbi F, et al. Childhood-onset of primary Sjogren\u2019s syndrome: phenotypic characterization at diagnosis of 158 children. Rheumatology (Oxford). 2021;60(10):4558\u201367.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"772_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2016","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology\/European League Against Rheumatism Classification criteria for primary Sjogren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2016;69(1):35\u201345.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"772_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12969-022-00740-4","volume":"20","author":"RL Randell","year":"2022","unstructured":"Randell RL, Stern SM, Van Mater H, Schanberg LE, Lieberman SM, Basiaga ML. Pediatric rheumatologists\u2019 perspectives on diagnosis, treatment, and outcomes of Sjogren disease in children and adolescents. Pediatr Rheumatol Online J. 2022;20(1):79.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"772_CR8","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.semarthrit.2020.11.004","volume":"51","author":"A Marino","year":"2021","unstructured":"Marino A, Romano M, Giani T, Gaggiano C, Costi S, Singh R, et al. Childhood Sjogren\u2019s syndrome: an Italian case series and a literature review-based cohort. Semin Arthritis Rheum. 2021;51(4):903\u201310.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"772_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1542\/peds.114.1.9","volume":"114","author":"O Nahlieli","year":"2004","unstructured":"Nahlieli O, Shacham R, Shlesinger M, Eliav E. Juvenile recurrent parotitis: a new method of diagnosis and treatment. Pediatrics. 2004;114(1):9\u201312.","journal-title":"Pediatrics"},{"issue":"1","key":"772_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ohn.960","volume":"172","author":"AG Holley","year":"2025","unstructured":"Holley AG, Stern SM, Park AH. Outcomes from a multidisciplinary otolaryngology and rheumatology clinic for the management of chronic sialadenitis. Otolaryngol Head Neck Surg. 2025;172(1):137\u201343.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"772_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/acr.23839","volume":"72","author":"DS Hammenfors","year":"2020","unstructured":"Hammenfors DS, Valim V, Bica B, Pasoto SG, Lilleby V, Nieto-Gonzalez JC, et al. Juvenile Sjogren\u2019s syndrome: clinical characteristics with focus on salivary gland ultrasonography. Arthritis Care Res (Hoboken). 2020;72(1):78\u201387.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"772_CR12","unstructured":"Flores-Chavez A, Kostov B, Solans R, Fraile G, Maure B, Feijoo-Masso C, et al. Severe, life-threatening phenotype of primary Sjogren\u2019s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 2018;36 Suppl. 112(3):121\u20139."},{"issue":"3","key":"772_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004201","volume":"10","author":"GE Legger","year":"2024","unstructured":"Legger GE, Nakshbandi U, van Ginkel MS, Liefers SC, de Wolff L, Stel AJ, et al. More severe parotid gland histopathology in paediatric-onset than in adult-onset Sjogren\u2019s disease. RMD Open. 2024;10(3):e004201.","journal-title":"RMD Open"},{"key":"772_CR14","unstructured":"De Vita S, Gandolfo S, Zandonella Callegher S, Zabotti A, Quartuccio L. The evaluation of disease activity in Sjogren\u2019s syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study. Clin Exp Rheumatol. 2018;36 Suppl. 112(3):150\u20136."},{"issue":"3","key":"772_CR15","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1016\/S2665-9913(25)00283-8","volume":"8","author":"C Ciurtin","year":"2026","unstructured":"Ciurtin C, Peng J, Taylor-Gotch R, Peckham H, Wilson R, Al Obaidi M, et al. Clinical phenotypes, classification, and long-term outcomes of childhood-onset Sjogren\u2019s disease into adulthood: a single-centre cohort study. Lancet Rheumatol. 2026;8(3):e204\u201316.","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"772_CR16","first-page":"381","volume":"17","author":"J Bartunkova","year":"1999","unstructured":"Bartunkova J, Sediva A, Vencovsky J, Tesar V. Primary Sjogren\u2019s syndrome in children and adolescents: proposal for diagnostic criteria. Clin Exp Rheumatol. 1999;17(3):381\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"772_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/art.1780360309","volume":"36","author":"C Vitali","year":"1993","unstructured":"Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjogren\u2019s syndrome: results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36(3):340\u20137.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"772_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.rdc.2021.07.008","volume":"47","author":"RL Randell","year":"2021","unstructured":"Randell RL, Lieberman SM. Unique aspects of pediatric Sjogren disease. Rheum Dis Clin North Am. 2021;47(4):707\u201323.","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"772_CR19","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S2665-9913(24)00059-6","volume":"6","author":"W Zeng","year":"2024","unstructured":"Zeng W, Thatayatikom A, Winn N, Lovelace TC, Bhattacharyya I, Schrepfer T, et al. The Florida Scoring System for stratifying children with suspected Sjogren\u2019s disease: a cross-sectional machine learning study. Lancet Rheumatol. 2024;6(5):e279\u201390.","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"772_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000022","volume":"1","author":"R Seror","year":"2015","unstructured":"Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. EULAR Sjogren\u2019s syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015;1(1):e000022.","journal-title":"RMD Open"},{"issue":"6","key":"772_CR21","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.2010.143743","volume":"70","author":"R Seror","year":"2011","unstructured":"Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjogren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren\u2019s syndrome. Ann Rheum Dis. 2011;70(6):968\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"772_CR22","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","volume":"3","author":"S Arends","year":"2021","unstructured":"Arends S, de Wolff L, van Nimwegen JF, Verstappen G, Vehof J, Bombardieri M, et al. Composite of relevant endpoints for Sjogren\u2019s syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol. 2021;3(8):e553\u201362.","journal-title":"Lancet Rheumatol."},{"issue":"7","key":"772_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","volume":"81","author":"R Seror","year":"2022","unstructured":"Seror R, Baron G, Camus M, Cornec D, Perrodeau E, Bowman SJ, et al. Development and preliminary validation of the Sjogren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjogren\u2019s syndrome. Ann Rheum Dis. 2022;81(7):979\u201389.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"772_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12969-022-00779-3","volume":"21","author":"Y Gong","year":"2023","unstructured":"Gong Y, Liu H, Li G, Zhang T, Li Y, Guan W, et al. Childhood-onset primary Sjogren\u2019s syndrome in a tertiary center in China: clinical features and outcome. Pediatr Rheumatol Online J. 2023;21(1):11.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"772_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40463-023-00658-1","volume":"52","author":"D Soriano-Martin","year":"2023","unstructured":"Soriano-Martin D, Garcia-Consuegra L, Junquera L, Rodriguez-Santamarta T, Olay S, Junquera-Olay S. Sialendoscopy approach in treating juvenile recurrent parotitis: a systematic review. J Otolaryngol Head Neck Surg. 2023;52(1):53.","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"772_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.011","volume":"52","author":"A Pomorska","year":"2022","unstructured":"Pomorska A, Swieton D, Lieberman SM, Bryl E, Kosiak W, Peksa R, et al. Recurrent or persistent salivary gland enlargement in children: when is it Sjogren\u2019s? Semin Arthritis Rheum. 2022;52:151945.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"772_CR27","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/annrheumdis-2019-215024","volume":"78","author":"S Jousse-Joulin","year":"2019","unstructured":"Jousse-Joulin S, D\u2019Agostino MA, Nicolas C, Naredo E, Ohrndorf S, Backhaus M, et al. Video clip assessment of a salivary gland ultrasound scoring system in Sjogren\u2019s syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise. Ann Rheum Dis. 2019;78(7):967\u201373.","journal-title":"Ann Rheum Dis"},{"key":"772_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152473","volume":"67","author":"D Rebel","year":"2024","unstructured":"Rebel D, de Wolff L, Delli K, Stel AJ, Kokol HC, Vissink A, et al. Added value of the salivary gland ultrasonography OMERACT score in the ACR\/EULAR classification criteria for Sjogren\u2019s disease. Semin Arthritis Rheum. 2024;67:152473.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"772_CR29","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s10067-025-07369-0","volume":"44","author":"J Yang","year":"2025","unstructured":"Yang J, Park Y, Lee JJ, Kim WU, Park SH, Kwok SK. Clinical value of salivary gland ultrasonography in evaluating secretory function, disease activity, and lymphoma risk factors in primary Sjogren\u2019s syndrome. Clin Rheumatol. 2025;44(4):1643\u201352.","journal-title":"Clin Rheumatol"},{"key":"772_CR30","unstructured":"Treemarcki E BM, Lieberman S, Stern S. Medication use in childhood Sjogren disease [abstract no. 1947]. Arthritis Rheumatol. 2022;74. (suppl 9)."},{"issue":"3","key":"772_CR31","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/rheumatology\/keab579","volume":"61","author":"G Doolan","year":"2022","unstructured":"Doolan G, Faizal NM, Foley C, Al-Obaidi M, Jury EC, Price E, et al. Treatment strategies for Sjogren\u2019s syndrome with childhood onset: a systematic review of the literature. Rheumatology (Oxford). 2022;61(3):892\u2013912.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"772_CR32","first-page":"2249","volume":"54","author":"S De Vita","year":"2015","unstructured":"De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, et al. Efficacy and safety of belimumab given for 12 months in primary Sjogren\u2019s syndrome: the BELISS open-label phase II study. Rheumatology (Oxford). 2015;54(12):2249\u201356.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"772_CR33","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","volume":"74","author":"X Mariette","year":"2015","unstructured":"Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjogren\u2019s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"772_CR34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","volume":"77","author":"BA Fisher","year":"2018","unstructured":"Fisher BA, Everett CC, Rout J, O\u2019Dwyer JL, Emery P, Pitzalis C, et al. Effect of rituximab on a salivary gland ultrasound score in primary Sjogren\u2019s syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis. 2018;77(3):412\u20136.","journal-title":"Ann Rheum Dis"},{"key":"772_CR35","unstructured":"Marketos N, Cinoku I, Rapti A, Mavragani CP. Type I interferon signature in Sjogren\u2019s syndrome: pathophysiological and clinical implications. Clin Exp Rheumatol. 2019;37 Suppl. 118(3):185\u201391."},{"issue":"12","key":"772_CR36","first-page":"2336","volume":"42","author":"C Baldini","year":"2024","unstructured":"Baldini C, Chatzis LG, Fulvio G, La Rocca G, Pontarini E, Bombardieri M. Pathogenesis of Sjogren\u2019s disease: one year in review 2024. Clin Exp Rheumatol. 2024;42(12):2336\u201343.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"772_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0049-0172(84)90001-5","volume":"14","author":"RI Fox","year":"1984","unstructured":"Fox RI, Howell FV, Bone RC, Michelson P. Primary Sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum. 1984;14(2):77\u2013105.","journal-title":"Semin Arthritis Rheum"},{"key":"772_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2026.102739","volume":"99","author":"GM Verstappen","year":"2026","unstructured":"Verstappen GM, Pringle S, van der Geest KS, Kroese FG, Bootsma H. T cells in Sjogren\u2019s disease: update on their role in salivary gland pathogenesis and treatment. Curr Opin Immunol. 2026;99:102739.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"772_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/rheumatology\/kez255","volume":"59","author":"S Colafrancesco","year":"2020","unstructured":"Colafrancesco S, Priori R, Smith CG, Minniti A, Iannizzotto V, Pipi E, et al. CXCL13 as biomarker for histological involvement in Sjogren\u2019s syndrome. Rheumatology (Oxford). 2020;59(1):165\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"772_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.41451","volume":"5","author":"J He","year":"2022","unstructured":"He J, Chen J, Miao M, Zhang R, Cheng G, Wang Y, et al. Efficacy and safety of low-dose interleukin 2 for primary Sjogren syndrome: a randomized clinical trial. JAMA Netw Open. 2022;5(11):e2241451.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"772_CR41","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","volume":"2","author":"EHM van der Heijden","year":"2020","unstructured":"van der Heijden EHM, Blokland SLM, Hillen MR, Lopes APP, van Vliet-Moret FM, Rosenberg A, et al. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjogren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol. 2020;2(5):e260\u20139.","journal-title":"Lancet Rheumatol."},{"issue":"4","key":"772_CR42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1586\/1744666X.2014.891439","volume":"10","author":"FG Kroese","year":"2014","unstructured":"Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H. B-cell hyperactivity in primary Sjogren\u2019s syndrome. Expert Rev Clin Immunol. 2014;10(4):483\u201399.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"772_CR43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1601-0825.2009.01582.x","volume":"15","author":"N Roescher","year":"2009","unstructured":"Roescher N, Tak PP, Illei GG. Cytokines in Sjogren\u2019s syndrome. Oral Dis. 2009;15(8):519\u201326.","journal-title":"Oral Dis"},{"issue":"1","key":"772_CR44","doi-asserted-by":"publisher","first-page":"R2","DOI":"10.1186\/ar3220","volume":"13","author":"EA Szyszko","year":"2011","unstructured":"Szyszko EA, Brokstad KA, Oijordsbakken G, Jonsson MV, Jonsson R, Skarstein K. Salivary glands of primary Sjogren\u2019s syndrome patients express factors vital for plasma cell survival. Arthritis Res Ther. 2011;13(1):R2.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"772_CR45","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1002\/art.30295","volume":"63","author":"AA Bookman","year":"2011","unstructured":"Bookman AA, Shen H, Cook RJ, Bailey D, McComb RJ, Rutka JA, et al. Whole stimulated salivary flow: correlation with the pathology of inflammation and damage in minor salivary gland biopsy specimens from patients with primary Sjogren\u2019s syndrome but not patients with sicca. Arthritis Rheum. 2011;63(7):2014\u201320.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"772_CR46","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/1529-0131(200111)44:11<2633::AID-ART443>3.0.CO;2-9","volume":"44","author":"N Amft","year":"2001","unstructured":"Amft N, Curnow SJ, Scheel-Toellner D, Devadas A, Oates J, Crocker J, et al. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren\u2019s syndrome. Arthritis Rheum. 2001;44(11):2633\u201341.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"772_CR47","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/art.21062","volume":"52","author":"F Barone","year":"2005","unstructured":"Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren\u2019s syndrome. Arthritis Rheum. 2005;52(6):1773\u201384.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"772_CR48","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1093\/rheumatology\/kev420","volume":"55","author":"N Thompson","year":"2016","unstructured":"Thompson N, Isenberg DA, Jury EC, Ciurtin C. Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjogren\u2019s syndrome. Rheumatology (Oxford). 2016;55(9):1548\u201355.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"772_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","volume":"17","author":"P Schneider","year":"2005","unstructured":"Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005;17(3):282\u20139.","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"772_CR50","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"F Mackay","year":"2009","unstructured":"Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491\u2013502.","journal-title":"Nat Rev Immunol"},{"issue":"10320","key":"772_CR51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","volume":"399","author":"SJ Bowman","year":"2022","unstructured":"Bowman SJ, Fox R, Dorner T, Mariette X, Papas A, Grader-Beck T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022;399(10320):161\u201371.","journal-title":"Lancet"},{"issue":"3","key":"772_CR52","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","volume":"63","author":"D Xu","year":"2024","unstructured":"Xu D, Fang J, Zhang S, Huang C, Huang C, Qin L, et al. Efficacy and safety of telitacicept in primary Sjogren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology (Oxford). 2024;63(3):698\u2013705.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"772_CR53","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/ard-2023-224691","volume":"83","author":"T Dorner","year":"2024","unstructured":"Dorner T, Kaul M, Szanto A, Tseng JC, Papas AS, Pylvaenaeinen I, et al. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis. 2024;83(3):360\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"10518","key":"772_CR54","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1016\/S0140-6736(25)01430-8","volume":"406","author":"G Noaiseh","year":"2025","unstructured":"Noaiseh G, Sivils KL, Campbell K, Idokogi J, Lo KH, Liva SG, et al. Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjogren\u2019s disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial. Lancet. 2025;406(10518):2435\u201348.","journal-title":"Lancet"},{"issue":"2","key":"772_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S, Nowak RJ, Farmakidis C, Bril V, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105\u201316.","journal-title":"Lancet Neurol"},{"issue":"7","key":"772_CR56","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/1744666X.2018.1485492","volume":"14","author":"K Jobling","year":"2018","unstructured":"Jobling K, Ng WF. CD40 as a therapeutic target in Sjogren\u2019s syndrome. Expert Rev Clin Immunol. 2018;14(7):535\u20137.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"772_CR57","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","volume":"30","author":"EW St Clair","year":"2024","unstructured":"St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, et al. CD40 ligand antagonist dazodalibep in Sjogren\u2019s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024;30(6):1583\u201392.","journal-title":"Nat Med"},{"issue":"10452","key":"772_CR58","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","volume":"404","author":"BA Fisher","year":"2024","unstructured":"Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, et al. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Lancet. 2024;404(10452):540\u201353.","journal-title":"Lancet"},{"issue":"3","key":"772_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005557","volume":"11","author":"N Shen","year":"2025","unstructured":"Shen N, Weinmann-Menke J, Malvar A, Serra-Roma A, Weiss M, Danekula R, et al. Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study. RMD Open. 2025;11(3):e005557.","journal-title":"RMD Open"},{"issue":"2","key":"772_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","volume":"37","author":"GI Rice","year":"2017","unstructured":"Rice GI, Melki I, Fremond ML, Briggs TA, Rodero MP, Kitabayashi N, et al. Assessment of type I interferon signaling in pediatric inflammatory disease. J Clin Immunol. 2017;37(2):123\u201332.","journal-title":"J Clin Immunol"},{"key":"772_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127417","volume":"14","author":"Q Zhan","year":"2023","unstructured":"Zhan Q, Zhang J, Lin Y, Chen W, Fan X, Zhang D. Pathogenesis and treatment of Sjogren\u2019s syndrome: review and update. Front Immunol. 2023;14:1127417.","journal-title":"Front Immunol"},{"issue":"12","key":"772_CR62","first-page":"2069","volume":"43","author":"R Li","year":"2025","unstructured":"Li R, Jia Y, Wu X, Wang M, Deng C, Peng Y, et al. Dysregulated plasmacytoid dendritic cells in primary Sjogren\u2019s syndrome: normal functionality but decreased quantities. Clin Exp Rheumatol. 2025;43(12):2069\u201381.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"772_CR63","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1136\/ard-2023-224842","volume":"83","author":"S Gupta","year":"2024","unstructured":"Gupta S, Yamada E, Nakamura H, Perez P, Pranzatelli TJ, Dominick K, et al. Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjogren\u2019s disease. Ann Rheum Dis. 2024;83(8):1034\u201347.","journal-title":"Ann Rheum Dis"},{"key":"772_CR64","unstructured":"Best Pharmaceuticals for Children Act. Washington, DC: Government Publishing Office; 2002: Report No.: Public Law 107-109, 115 Stat. 1408."},{"key":"772_CR65","unstructured":"U.S. Food and Drug Administration. Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans: Guidance for Industry. Silver Spring, MD: Food and Drug Administration; July 2020."},{"key":"772_CR66","unstructured":"EMA decision of 9 October 2018 granting a product-specific waiver for ianalumab (EMEA-002338-PIP02-18). Amsterdam: European Medicines Agency; 2018."},{"issue":"3","key":"772_CR67","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","volume":"20","author":"M Beydon","year":"2024","unstructured":"Beydon M, McCoy S, Nguyen Y, Sumida T, Mariette X, Seror R. Epidemiology of Sjogren syndrome. Nat Rev Rheumatol. 2024;20(3):158\u201369.","journal-title":"Nat Rev Rheumatol"},{"key":"772_CR68","unstructured":"Pediatric Research Equity Act of 2003. Washington, DC: U.S. Government Publishing Office; 2003."},{"key":"772_CR69","unstructured":"Adult-related conditions that qualify for a waiver because they rarely or never occur in pediatrics. Silver Spring: US Food and Drug Administration; 2024."},{"key":"772_CR70","unstructured":"E11A pediatric extrapolation: guidance for industry. Silver Spring: US Food and Drug Administration; 2024."},{"issue":"10","key":"772_CR71","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"772_CR72","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/clpt.2013.177","volume":"95","author":"HP Selker","year":"2014","unstructured":"Selker HP, Oye KA, Eichler HG, Stockbridge NL, Mehta CR, Kaitin KI, et al. A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials. Clin Pharmacol Ther. 2014;95(2):147\u201353.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"772_CR73","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145\u201354.","journal-title":"Nat Rev Rheumatol"},{"key":"772_CR74","unstructured":"Grader-Beck T, Mariette X, Finzel S, Schiopu E, Papas A, Devauchelle-Pensec V, et al. Ianalumab demonstrates significant reduction in disease activity in patients with Sj\u00f6gren\u2019s disease: efficacy and safety results from two global phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2) [abstract]. Arthritis Rheumatol. 2025;77."},{"key":"772_CR75","unstructured":"Dong X, Shangzhu Z, Qiao L, Zhang L, Wang W, Li L, et al. Efficacy and safety of telitacicept in patients with Sj\u00f6gren\u2019s disease: results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study [abstract]. Arthritis Rheumatol. 2025;77."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00772-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00772-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00772-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:20:11Z","timestamp":1790007611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00772-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":75,"alternative-id":["772"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00772-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sara M. Stern, Ludovic Trinquart, Hermine Brunner, Marisha E. Palm, and Nora G. Singer have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SMS, LT, HB, MEP, and NGS contributed to the conceptualization and manuscript drafting. All authors contributed to the revision of the article and approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}